Early in the morning of Feb. 21, Change Healthcare, a company unknown to most Americans that plays a huge role in the U.S. health system, issued a brief statement saying some of its applications were “currently unavailable.”
Regeneron and Sanofi’s Dupixent bags fifth drug label in Japan – Pharmaceutical Technology
Share this article Dupixent has been approved as a treatment for chronic spontaneous urticaria (CSU) in patients aged 12 and older whose symptoms are inadequately